Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines

Introduction

Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that could reach $3.4 billion in infants and adults across the US and 5EU by 2019, leaving only marginal roles for its competitors. The commercial opportunity for MenACWY conjugate vaccines will largely remain restricted to the US, while a broad MenB vaccine could achieve blockbuster status.

Features and benefits

* In-depth analysis of market dynamics for pneumo-and meningococcal vaccines across US, 5EU and Japan, supported by insights of key opinion leaders
* Population-based 10-year sales forecasts for currently available brands and late-stage pipeline vaccines in the US and 5EU.
* Epidemiology section discussing key population trends and epidemiological features of pneumo- and meningococcal disease in the seven major markets
* Thorough assessments of key marketed vaccines and late stage pipeline products.

Highlights

Datamonitor anticipates the launch of Pfizer’s Prevnar 13 for adults in 2011 and expects the vaccine to quickly replace Merck & Co's Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.4 billion in 2019 across the US and five major EU markets.
Sales expectations for conjugate MenACWY vaccines are limited in the seven major markets. While the US are unlikely to recommend routine MenACWY vaccination of infants, MenACWY vaccines will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs. Best growth opportunities lie in a meningococcal B vaccine.
Pneumo- and meningococcal vaccines continue to offer great commercial opportunities due to changing disease epidemiology and extension of age indications. Novartis’ 4CMenB is the most promising pipeline vaccine and expected to quickly reach blockbuster status with possible sales of almost $3 billion in the US and the five major European ma

Your key questions answered

* Identify the market dynamics of pneumo- and meningococcal vaccines, success factors for leading brands and the potential of late stage pipeline
* Obtain full country and product-specific forecasts of currently marketed and pipeline pneumo- and meningococcal vaccines from 2010 to 2019.
* Understand epidemiological trends of pneumo-and meningococcal disease across the seven major markets and their impact on vaccination recommendations
[Studien Infos ausblenden]

Executive Summary
Strategic scoping and focus
Datamonitor insight into the pneumococcal and meningococcal vaccines market
Related reports
Upcoming related reports
OVERVIEW
Catalyst
Summary
PNEUMOCOCCAL VACCINES
Summary
Pneumococcal disease background
Epidemiological context
Introduction
Key points
Disease definition and diagnosis criteria
Surveillance of invasive pneumococcal disease
Impact of vaccines
Serotype replacement
Market-specific epidemiology
Epidemiologic forecasting of IPD vaccine-eligible population
Results
Discussion
Vaccination recommendations
Infants
Adults and elderly
Vaccination coverage
Infants
Adults and elderly
Overview of the competitive landscape
Four vaccines are marketed for the prevention of infection with S. pneumoniae
There are different strategies to boost the primary immune response of conjugate vaccines
Key companies and strategies
Pfizer – clear dominance through Prevnar franchise
Merck & Co – increasing pressure for Pneumovax
GlaxoSmithKline – emerging markets as an expansion strategy for Synflorix
Deals with GAVI provide an opportunity to penetrate developing markets
Unmet needs
Marketed and pipeline vaccines
Pneumovax (23-valent pneumococcal polysaccharide vaccine, Merck & Co)
Prevnar 7 (7-valent pneumococcal conjugate vaccine, Pfizer)
Prevnar 13 (13-valent pneumococcal conjugate vaccine, Pfizer)
Synflorix (10-valent pneumococcal conjugate vaccine, GlaxoSmithKline)
Pneumococcal vaccines pipeline
Market opportunity and forecast
Growth of overall pneumococcal vaccines market will be driven by launch of Prevnar 13 in adults
Pneumococcal infant market will see further expansion following the launch of Prevnar 13
Assumptions made for forecasting the pneumococcal vaccines market
Country forecasts
MENINGOCOCCAL VACCINES
Summary
Disease background
Serogroups causing disease vary in the seven major markets
Protection against N. meningitidis is assessed by serum bactericidal antibody assay
Epidemiologic context
Introduction
Key points
Disease definition and diagnosis criteria
Surveillance of meningococcal disease
Serotypes
Behavioral risk factors for meningococcal disease
Market-specific epidemiology
Epidemiologic forecasting of meningococcal vaccine-eligible population
Results
Discussion
Vaccination recommendations
US
Japan
France
Germany
Italy
Spain
UK
Coverage
US
Japan
France
Germany
Italy
Spain
UK
Overview of competitive landscape
Across Europe, MenC vaccines remain the gold standard in infant immunization schedules
In the US, Novartis’s Menveo challenges Menactra’s market dominance
In Japan, no meningococcal vaccine has been approved so far
Key companies and strategies
Most major vaccine players have a portfolio in meningococcal vaccines
Sanofi Pasteur
Novartis
GlaxoSmithKline
Unmet needs
Marketed and pipeline vaccines
Menactra (conjugate N. meningitidis ACWY vaccine, Sanofi Pasteur))
Menveo (conjugate N. meningitidis ACWY vaccine, Novartis)
Menomune (polysaccharide N. meningitidis ACWY vaccine, Sanofi Pasteur)
Vaccines against N. meningitidis serogroup C (MenC vaccines)
Menitorix (conjugate N. meningitidis C and Haemophilus influenzae type b vaccine, GlaxoSmithKline)
MenAfriVac (N. meningitidis serogroup A conjugate vaccine, Serum Institute of India/WHO/PATH)
Nimenrix (conjugate N. meningitidis ACWY vaccine, GlaxoSmithKline)
MenHibrix (conjugate N. meningitidis CY and Haemophilus influenzae type b vaccine, GlaxoSmithKline)
TetraMen-T (conjugate N. Meningitidis ACWY vaccine, Sanofi Pasteur)
Overview of meningococcal serogroup B vaccines
4CMenB (Meningitis B vaccine, Novartis Vaccines & Diagnostics)
MnB rLP2086 (Meningitis B vaccine, Pfizer Inc.)
Other meningococcal vaccines in early-stage development
Market opportunity and forecast
MenACWY vaccines are unlikely to be recommended routinely in the five major EU markets in the short- to mid-term
MenACWY not expected to become routinely recommended in infants in the US
MenB sales are expected to reach $2.8 billion in 2019 across the US and the five major European markets
Assumptions made for forecasting the meningococcal vaccine market
Country forecasts
BIBLIOGRAPHY
Literature
APPENDIX A
Forecasts
Forecast methodology
Datamonitor’s forecast methodology
Datamonitor’s patient-based forecasting model
APPENDIX B
US and five major European countries
US
Five major EU markets
France
Germany
Italy
Spain
UK
APPENDIX C
Contributing experts
Report methodology
[Inhaltsverzeichnis ausblenden]